 "Glenmark licenses oncology products from US-based APC Therapeutics")
Glenmark Pharmaceuticals has entered into a licensing agreement with Boston-based APC Therapeutics Inc, a biopharmaceutical company focused on building a portfolio of best-in-class immuno-oncology (IO) therapies, for exclusive rights to a small molecule, oncology compound based on Antigen Presenting Cell (APC) biology. The compound has the potential to be used as a monotherapy or in combination with approved therapies to address unmet needs in cancer treatment.
“This asset adds to our robust biologics pipeline of targeted IO therapies. The mechanism of action of APC biology is very intriguing and has the potential to be transformative in cancer treatment by triggering powerful immunologic responses to tumors that may lead to deeper and more durable responses to treatment,” said Kurt Stoeckli, president and chief scientific officer, Glenmark Pharmaceuticals.
Under the terms of the agreement, Glenmark will license the product from APC Therapeutics, and manage all clinical development including regulatory filings and commercialisation worldwide. APC Therapeutics will receive development milestones and sales royalty payments.
“Glenmark is an ideal partner to advance such an important scientific breakthrough treatment to patients with cancer. This partnership is strategically significant for APC Therapeutics as it validates and advances our commitment to bring the right immunotherapies to the right patient populations,” said Vinod Patel and Venkateshwar Reddy, the co-founders of APC Therapeutics.
The global oncology market is growing exponentially and projected to exceed $ 150 billion by 2020, according to figures from IMS Health. Driving this growth is the transition from short-term cytotoxic treatments towards precision medicines, most notably immune-oncology agents providing substantial increase in long-term survival. Because of these improvements, IO is one of the most promising and fastest growing areas of cancer treatment and research.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%